Hutchinson-Gilford Progeria Syndrome (HGPS) Market Report 2026

The hutchinson-gilford progeria syndrome (hgps) market size has grown strongly in recent years. It will grow from $106.25 billion in 2025 to $115.56 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to identification of lmna gene mutation, lack of curative treatment options, reliance on supportive and symptomatic care, limited patient population size, increased involvement of rare disease foundations.

The hutchinson-gilford progeria syndrome (hgps) market size is expected to see strong growth in the next few years. It will grow to $160 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to advancements in gene therapy and crispr-cas9 technologies, growing investment in ultra-rare disease research, expanding clinical trials for disease-modifying therapies, increasing global awareness of progeria, rising regulatory support for orphan drugs. Major trends in the forecast period include increasing focus on gene editing and antisense therapies for progeria, growing adoption of targeted drug therapies such as farnesyltransferase inhibitors, rising emphasis on early genetic diagnosis and counseling, expansion of multidisciplinary supportive care models, increasing research collaboration for ultra-rare pediatric disorders.

The increasing funding for research and development of new therapies is expected to drive the growth of the Hutchinson-Gilford Progeria Syndrome (HGPS) market in the coming years. Funding for research and development refers to financial resources allocated to innovate, improve, and advance scientific knowledge and technological solutions. This increase is fueled by rising demand for innovative treatments and government support for healthcare advancements. Greater R&D funding accelerates the development of HGPS therapies by supporting clinical trials and fostering novel treatment approaches. It also advances understanding of the genetic origins of the condition and facilitates the creation of targeted solutions. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, a significant acceleration compared to the 0.9% growth in 2022. Therefore, rising R&D investment is driving the growth of the HGPS market.

Key companies in the HGPS market are focusing on progerin-targeted therapeutics, including antisense and small-molecule agents such as Progerinin, to develop next-generation treatment approaches. For instance, in October 2024, PRG Science & Technology, a South Korea-based biotech company, received FDA clearance to begin a Phase 2a clinical trial of Progerinin. This oral therapy is designed to reduce progerin accumulation and will be evaluated in combination with Zokinvy. The combined strategy aims to target the underlying biological cause of HGPS rather than addressing only downstream symptoms. While this approach shows promise for advancing treatment beyond current options, its long-term safety and efficacy in children still require further clinical evaluation.

In May 2024, Sentynl Therapeutics, Inc., a US-based biopharmaceutical company, acquired Zokinvy from Eiger BioPharmaceuticals, Inc. for an undisclosed amount. Through this acquisition, Sentynl aims to address the unmet medical needs of patients with ultra-rare genetic conditions that cause accelerated aging and significantly reduce life expectancy. Eiger BioPharmaceuticals, Inc., a US-based biopharmaceutical company, developed Zokinvy (lonafarnib) specifically for the treatment of HGPS.

Major companies operating in the hutchinson-gilford progeria syndrome (hgps) market are Sentynl Therapeutics, Progeria Research Foundation, National Institutes of Health, Boston Children's Hospital, Children's Hospital of Philadelphia, Johns Hopkins Hospital, Mayo Clinic, Cleveland Clinic, Mount Sinai, Duke University, St Jude Children's Research Hospital, Cincinnati Children's Hospital Medical Center, Children’s Hospital Los Angeles, Harvard Medical School, The Scripps Research Institute, Blueprint Genetics, AnGes MG Inc., PRG Science & Technology Co. Ltd., University of Maryland School of Medicine, UCLA Health.

North America was the largest region in the hutchinson-gilford progeria syndrome (HGPS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hutchinson-gilford progeria syndrome (hgps) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hutchinson-gilford progeria syndrome (hgps) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hutchinson-gilford progeria syndrome market by increasing the cost of imported active pharmaceutical ingredients, gene therapy vectors, and specialized research equipment required for rare disease drug development. These impacts are most pronounced in advanced therapeutic segments and in regions such as North America and Europe that rely on global biopharmaceutical supply chains. While higher costs may affect development timelines, tariffs are also encouraging localized manufacturing, regional sourcing of critical inputs, and increased investment in domestic rare disease research infrastructure, supporting long-term market resilience.

The hutchinson-gilford progeria syndrome (hgps) market research report is one of a series of new reports that provides hutchinson-gilford progeria syndrome (hgps) market statistics, including hutchinson-gilford progeria syndrome (hgps) industry global market size, regional shares, competitors with a hutchinson-gilford progeria syndrome (hgps) market share, detailed hutchinson-gilford progeria syndrome (hgps) market segments, market trends and opportunities, and any further data you may need to thrive in the hutchinson-gilford progeria syndrome (hgps) industry. This hutchinson-gilford progeria syndrome (hgps) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hutchinson-Gilford Progeria Syndrome (HGPS), also known as progeria, is an extremely rare and fatal genetic disorder that causes accelerated aging in children. It is caused by mutations in the LMNA gene, leading to symptoms such as growth delays, hair loss, premature skin wrinkling, and cardiovascular complications. The average life expectancy for individuals with progeria is approximately 14.5 years.

The main treatment types for HGPS include farnesyltransferase inhibitors (e.g., Zokinvy [lonafarnib]), low-dose aspirin, physical and occupational therapy, hearing aids, genetic counseling, and other supportive measures. Farnesyltransferase inhibitors like Zokinvy block the enzyme responsible for protein modification, providing a targeted therapy that may help prevent premature aging and improve outcomes in children with HGPS. Treatments are administered via various routes, including oral, injectable, intravenous, and transdermal methods, and utilize mechanisms such as antisense oligonucleotides, CRISPR-Cas9 gene editing, RNA interference, and targeted drug delivery systems. These therapies are used by hospitals, specialty clinics, academic and research institutions, and other healthcare providers.

The hutchinson-gilford progeria syndrome (HGPS) market consists of revenues earned by entities by providing services such as genetic testing and diagnosis, drug development and clinical trials, specialized medical care and treatment, and patient support and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hutchinson-gilford progeria syndrome (HGPS) market also includes sales of pharmaceutical drugs, genetic testing kits, medical devices and monitoring equipment, nutritional supplements and special diet products, and assistive mobility devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.